A lesson learnt: The rise and fall of Lariam and Halfan

Journal of the Royal Society of Medicine

Volumn 100, Issue 4, 2007, Pages 170-174

  Croft, Ashley M ^a  

^a Headquarters 5th Division   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HALOFANTRINE; MEFLOQUINE;

ABNORMAL SENSATION; ASYSTOLE; BLISTER; BONE BURNING; CARDIOPULMONARY ARREST; CARDIOTOXICITY; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; COUGHING; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ERYTHEMA; HAIR LOSS; HEADACHE; HEARING IMPAIRMENT; HEART DISEASE; HUMAN; MALARIA; MENTAL DISEASE; NAIL DISEASE; NAIL LOSS; NEUROTOXICITY; ORAL BLISTER; PANIC; POSTMARKETING SURVEILLANCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUICIDE; ULCER; VENTRICULAR DYSRHYTHMIA;

EID: 34247866215     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.100.4.170     Document Type: Review

References (52)

1. Trenholme GN, Williams RL, Desjardins RE, et al. Mefloquine (WR 142,490) in the treatment of human malaria. Science 1975;190:792-4
2. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Suppressive activity of mefloquine in sporozoite-induced human malaria. Antimicrobial Agents Chemother 1976;9:384-6
3. Kitchen LW, Vaughn DW, Skillman DR. Role of US military research programs in the development of US Food and Drug Administration-approved antimalarial drugs. Clin Infect Dis 2006;43:67-71
4. Cosgriff TM, Boudreau EF, Pamplin CL, Doberstyn EB, Desjardins RE, Canfield CJ. Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669). Am J Trop Med Hyg 1982;31:1075-9
5. Croft AM, Geary K. Chloroquine and its combinations. In: Schlagenhauf P, ed. Travellers' Malaria. Hamilton, Ontario: Decker, 2001
6. Bruce-Chwatt LJ. John Hull Grundy lecture. Mosquitoes, malaria and war; then and now. J R Army Med Corps 1985;131:85-99
7. Tigertt WD. The Army malaria research program. Ann Intern Med 1969; 70: 150-3
8. Croft AM, Whitehouse DP, Cook GC, Beer MD. Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf 2002; 1: 19-27
9. Croft AM, Garner P, Squire SB. Malaria prevention for travelers. JAMA 1998; 279: 990
10. Magill AJ. Malaria: epidemiology and risk to the traveler. In: Keystone JS, Kozarsky PE, Freedman DO, Nothdurft HD, Connor BA, eds. Travel medicine. New York: Mosby, 2004: 131-6
11. Dow G, Bauman R, Caridha D, et al. Mefloquine-induces dose-related neurological effects in a rat model. Antimicrob Agents Chemother 2006; 50: 1045-53
12. Heeringa M, van Grootheest AC. Profylactisch gebruik van mefloquine - bijwerking geen reden tot verandering van indicatie. Pharmaceutisch Weekblad 2000; 135: 788-792
13. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized double-blind study. Clin Infect Dis 2001;33:1015-21
14. Potasman I, Juven Y, Weller B, Schwartz E. Does mefloquine prophylaxis affect electroencephalographic patterns? Am J Med 2002; 112: 147-9
15. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003; 327: 1078-81
16. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354: 119-30
17. Van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J Clin Psychiatry 2005; 66: 199-204
18. Anonymous. Mefloquine for malaria. Medical Letter on Drugs and Therapeutics 1990; 31: 13-4
19. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-6
20. McBride SR, Lawrence CM, Pape SA, Reid CA. Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. Lancet 1997; 349: 101
21. News report. Roche's Lariam linked to a suicide in UK. Scrip 1998; 2331: 23
22. Anonymous. Netwerk aktuell - Suizid nach zwei Tabletten Mefloquin (LARIAM). Arznei-telegramm 2000; 31: 23
23. Centers for Disease Control and Prevention. Sudden death in a traveler following halofantrine administration - Togo, 2000. Morb Mortal Wkly Rep 2001; 50: 169-70
24. Smith HR, Croft AM, Black MM. Dermatological adverse effects with the antimalarial drug, mefloquine: a review of 74 published case reports. Clin Exp Derm 1999; 24: 249-54
25. Nosten F, van Vugt M. Neuropsychiatric adverse effects of mefloquine. What do we know and what should we do? CNS Drugs 1999; 11: 1-8
26. Jousset N, Guilleux M, de Gentile L, Le Bouil A, Turcant A, Rougé-Maillart C. Suicide spectaculaire lié à une prise de méfloquine. Presse Med 2006; 35: 789-92
27. News report. FDA requires warnings on anti-malaria drug Lariam. Consum Rep 2004; 69: 45
28. Medication guide: Lariam [online]. Available at http://www.fda.gov/ medwatch/SAFETY/2003/LariamMedGuide.pdf (Accessed 02/11/2006)
29. Committee on Safety of Medicines. Mefloquine (Lariam) and neuropsychiatric reactions. Current Problems in Pharmacovigilance 1996; 2: 6
30. Warner J. Advice to warn patients about rare side effects overturns accepted practice. BMJ 1996; 313: 1554
31. Akhtar T, Imran M. Sudden deaths while on halofantrine treatments - a report of two cases from Peshawar. J Pak Med Assoc 1994; 44: 120-1
32. Malvy D, Receveur MC, Ozon P, et al. Fatal cardiac incident after use of halofantrine. J Travel Med 2000; 7: 215-6
33. Bouchaud O, Bruneel F, Schiemann R, Peytavin G, Coulaud JP. Severe cardiac toxicity due to halofantrine: importance of underlying heart disease. J Travel Med 2002; 9: 214-5
34. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-6
35. Shanks GD, Edstein MD. Modern malaria chemoprophylaxis. Drugs 2005; 65: 2091-110
36. th edition. New York: McGraw-Hill, 2006: 1021-47
37. Croft AM, Beer MD, Herxheimer A. Effectiveness of antimalarial drugs. N Engl J Med 2005; 353: 420-2
38. W Milhous. Development of new drugs for chemoprophylaxis of malaria. Bull Soc Pathol Exot 2001; 24: 149-51
39. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352: 1565-77
40. Burke BM. Mefloquine. Lancet 1993; 341: 1605-6
41. Croft AM, Garner P. Mefloquine for preventing malaria in non-immune adult travellers. The Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD000138. DOI: 10.1002/14651858.CD000138
42. News report. Canadian soldiers used as 'guinea pigs'? Can Med Assoc J 1999; 160: 1814
43. van Puijenbroek EP, Bouvy M. Mefloquine (Lariam) in het nieuws. Pharmaceutisch Weekblad 1995; 130: 912
44. News report. Lariam suicide warning. BMJ 2002; 325: 510
45. Burton B. Australian army faces legal action over mefloquine. BMJ 2004; 329: 1062
46. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006; 99: 337-41
47. Chalmers I. Under-reporting research is scientific misconduct. JAMA 1990; 263: 1405-8
48. Brown P, Brunnhuber K, Chalkidou K, et al. How to formulate research recommendations. BMJ 2006; 333: 804-6
49. Richardson WS, Wilson MC, Nishikawa J, Hayward RSA. The well-built clinical question: a key to evidence-based decisions. ACPJ Club 1995; 123: A12-A13
50. Croft AM, Herxheimer A. Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health 2002; 25: 6. Available at http://www. biomedcentral.com/my/access.asp?man_id=9039985831098605 (Accessed 02/11/2006)
51. Aarnoudse AL, van Schaik RH, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 2006; 80: 367-74
52. Whitty CJ, Lalloo D, Ustianowski A. Malaria - an update on treatment of adults in non-endemic countries. BMJ 2006; 333: 241-5